Editor's note

This article was originally published on 10 November 2014 as part of the VacZine Analytics ExpertREACT series. It is reproduced here for archival purposes. Market conditions, pipeline statuses and regulatory positions described reflect the state of knowledge at that date.

The QIV transition accelerates

In the 2013/14 US influenza season, quadrivalent vaccines (QIV) represented approximately 23% of volume (around 31 million doses). By the 2014/15 season that share had jumped to approximately 54% (76 million doses), with Sanofi Pasteur the dominant QIV supplier at an estimated 41.5 million doses. The US ACIP still did not express a preference for QIV over trivalent (TIV) formulations, but the commercial logic was clear: QIV commanded a 30-44% price premium per dose in the private sector.

QIV Market Share 2014/15
54%

Quadrivalent vaccines' share of the 2014/15 US influenza season, up from 23% in 2013/14

Fluzone HD: towards blockbuster territory

Sanofi's high-dose influenza vaccine Fluzone HD (60μg HA, four times standard content) continued to strengthen its position in the >65 years segment. Publication of the FIM12 study results - a 15,892-person randomised trial - showed that Fluzone HD reduced clinically relevant influenza by a further 24.2% versus standard Fluzone. Sanofi stated it sold approximately 8 million doses in the 2013/14 season and anticipated one in three elderly Americans could receive the vaccine in 2014/15. Our preliminary calculations suggested Fluzone HD could become a blockbuster product if penetration continued to grow in the globally ageing population.

New entrants and alternative platforms

Protein Sciences Corporation's baculovirus-expressed FluBlok, approved in 2013 for adults 18 and older, was a relative newcomer supplying approximately 500,000 doses to the 2014/15 season. Positioned as "triple strength" (45μg HA), FluBlok theoretically had potential in the >65 years segment if further studies were conducted, though production scale and global reach remained limited.

"Short-term success in life-cycle management is inhibiting long-term progress. The near-silence on universal flu vaccine from industry is striking."

The universal influenza vaccine gap

Most striking in 2014 was the near-absence of public commitment to universal influenza vaccine development from major manufacturers. US BARDA and Israeli company BiondVax remained interested, along with academic groups, but the major commercial players - Sanofi, GSK and MedImmune - made very few public statements on universal vaccine programmes. When life-cycle management of existing products is so commercially rewarding, the incentive to pursue the technically demanding and high-risk path to a universal vaccine becomes structurally weakened.